Maridebart Cafraglutide
A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations
Amgen · Phase 1 · Completed · Enrollment 349
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Maridebart Cafraglutide SC Presentation 1 | n/r | n/r | n/r | n/r | n/r |
| Maridebart Cafraglutide SC Presentation 2 | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.